Deallus white papers

The latest white papers from Deallus pharmaceutical and life science industry experts

Competitive Intelligence in an Agile World

2019-11-08T14:34:37+00:00White Paper|

Adapting competitive intelligence functions to an increasingly complex pharma landscape. This White Paper explores the concept of agile working for the pharma world, delving into the opportunities and challenges that arise for Competitive Intelligence teams and managers as working environments adapt to find success in a more dynamic, uncertain, and fast-paced environment.

Purchasing a Pipeline

2019-11-08T14:30:03+00:00White Paper|

Perils, pitfalls, and priorities in asset acquisition. In this White Paper, we will look at new and changing trends in pipeline acquisition, discuss difficulties inherent in the current marketplace, and offer worthwhile perspectives on pitfalls and opportunities based on our experience offering strategic guidance to pharmaceutical companies on a global scale.

The Three A’s of Launch Readiness

2020-02-12T11:48:23+00:00White Paper|

Drug launch failures happen more frequently than pharma companies care to admit. Anticipate, Adapt and Align - the three A’s of successful pharma launch strategy. To understand and implement them requires strategic vision, a holistic understanding of every vagary of the marketplace, and a forthright and ruthlessly honest assessment of both the product being launched and the competitive space it is meant to occupy.

Disruption has hit pharma

2020-02-12T10:02:43+00:00White Paper|

Strategic intelligence for a fiercely competitive marketplace. In the pharmaceutical industry, change has long been known as the only constant. But the last few years have seen the industry challenged and reshaped by drastic internal disruption and external paradigm shifts. Deallus look at key changes in the pharma landscape through the lens of strategic intelligence, and considers how this powerful tool can help pharma stakeholders grasp the full picture of the competitive environment they intend to enter.

Asia Market Entry

2020-06-22T08:14:43+01:00White Paper|

A continent of extremes, with great potential for growth. Geographically large, the assortment of cultures, people, disease profiles, and healthcare systems added to the juxtaposition of extreme wealth and extreme poverty, emphasises the many challenges faced by the pharmaceutical companies when thinking of entering Asia. Commercial success will depend on understanding the market dynamics by consolidating positioning within the market place with the requirements of each market.

Asian Pricing and Reimbursement

2020-02-12T10:28:49+00:00White Paper|

Growing major trends are emerging across Asian healthcare markets. Rising incomes, increased government healthcare expenditure, higher life expectancies and a surge of chronic illnesses are boosting the demand for pharmaceutical products and services in the region. We take a look at the emerging trends across Asian healthcare systems and the implications for the industry.